"Improved delivery devices for insulin treatment have increased patient compliance and acceptance of an intensive insulin strategy," which can result in significant reductions in long-term complications associated with poorly controlled type 1 and type 2 diabetes, says Satish Garg, Professor of Medicine and Pediatrics at the University of Colorado Denver.
The development of automated glucose-controlled insulin infusion systems that combine the advantages of continuous glucose measurement with intravenous insulin infusion pumps "is likely to explode over the next several years," predicts Jay Skyler, Professor at the University of Miami Miller School of Medicine in Florida.
Although insulin pump and pen technology have been available for quite some time, these devices are "underused, misused, or poorly used," states Irl Hirsch, MD, from the University of Washington School of Medicine in Seattle. He has recently reviewed the reasons for the poor use of diabetes technology worldwide and predicts increased adoption of these treatment devices in the coming decade.
Eric Renard at the University of Montpellier in France, presents the factors he believes have limited insulin pump use in Europe and the need for expanded insurance coverage and education to drive increased adoption of the technology. Bruce Bode, MD, a diabetes specialist describes the promise and advantages insulin pumps offer for improving glucose control in type 2 diabetes, based on early-stage clinical research in this area.
Riccardo Perfetti, PhD, explores the reasons for the marked geographical variation in the use of reusable and disposable insulin pens and concludes that the most important factor is likely varied access to the devices in different regions of the world. Perfetti also suggests that insulin pens have potential benefit for use in hospitalized patients, an application that has received too little attention.
MEDICA.de; Source:Mary Ann Liebert/ Genetic Engineering News